All blog posts
Total 15 results for
Showing 12 out of 15 results
23 12月 2025
Mixing it up: The end of the line for patent term extensions for formulation patents in Australia
15 12月 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
09 12月 2025
Preserving the status quo: Boehringer Ingelheim awarded interim injunction
02 12月 2025
UPC holds CE marking approval is evidence of imminent infringement and starts the clock running where considering any (unreasonable) delay in a PI application
03 9月 2025
Herbert Smith Freehills Kramer comments for LSIPR on small molecule litigation in the UPC
31 7月 2025
EU Regulatory Reform for Medicinal Products: Bolar exemption
30 7月 2025
When will modifying a chemical scaffold be inventive? The UK Court of Appeal opines in the Xtandi case
21 7月 2025
Trends emerging as the UPC enters its third year
19 5月 2025
IP licensing: take care when considering market practices
13 5月 2025
EU Regulatory Reform for Medicinal Products: Changes to MAs, supply, and transparency
30 4月 2025
EU Regulatory Reform for Medicinal Products: Review of new regulatory exclusivities
25 2月 2025
CJEU clears the way for single courts determining infringement actions in multiple jurisdictions without invalidity counterclaims interfering with the process (BSH Hausgerate v Electrolux)
Showing 12 out of 15 results
View moreKey contacts
Rebekah Gay
Partner, Head of Intellectual Property, Sydney
Laura Orlando
Managing Partner, Milan Office, Milan
Sue Gilchrist
Consultant, Sydney
雷鹏
科伟史密夫斐尔凯迈联营办公室合伙人, Mainland China and Shanghai
Alexandra Neri
Partner, Paris
Dr Ina vom Feld
Partner, Germany
Sebastian Moore
Partner, Head Intellectual Property, London and Milan
Rachel Montagnon
Knowledge Counsel, London